Journal Mobile Options
Table of Contents
Vol. 16, No. 2, 2001
Issue release date: March–April 2001
Fetal Diagn Ther 2001;16:111–115

Knowledge on Periconceptional Use of Folic Acid in Women of British Columbia

Morin V.I. · Mondor M. · Wilson R.D.
Children’s and Women’s Health Center of British Columbia, Vancouver, B.C., Canada

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: Our purpose was to evaluate the knowledge of folic acid and its use preconceptionally in women of British Columbia. Methods: The study was conducted at British Columbia Women’s Hospital in Vancouver, Canada, between April 15 and June 15, 1999. Pregnant women and women in the postpartum period were asked to complete a survey on folic acid. Results: In total, 1,004 women completed the questionnaire during the study period. Seventy-one percent of the women knew that vitamins could help prevent birth defects. Of those, 76.3% identified folic acid as the one vitamin specifically associated with reduction of birth defects. It was identified that 49.4% of all women took vitamins prior to pregnancy. Conclusions: Women in the population studied were relatively well informed about the benefits of folic acid, but less than 50% of them took vitamins prior to conception.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Thunem NY, Lowry RB, Tucker BJ, Medd BW: Birth prevalence and recurrence rates of neural tube defects in southern Alberta in 1970–81. Can Med Assoc J 1988;138:819–823.
  2. Hunter AGW: Neural tube defects in eastern Ontario and western Québec: Demography and family data. Am J Med Genet 1984;19:45–63.
  3. Society of Obstetricians and Gynecologists: L’emploi de l’acide folique pour la prévention des malformations du tube neural. Ottawa, Society of Obstetricians and Gynecologists, 1993.
  4. Van Allen MI, Fraser FC, Dallaire L, Allanson J, McLeod DR, Anderman E, Friedman JM: Recommendations on the use of folic acid supplementation to prevent the recurrence of neural tube defects. Can Med Assoc J 1993;149:1239–1243.
  5. Cohen FL: Neural tube defects: Epidemiology, detection, and prevention. J Obstet Gynecol Neonatal Nurs 1987;16:105–115.

    External Resources

  6. Dallaire M, Michaud J, Melançon SB: Prenatal diagnosis of fetal anomalies during the second trimester of pregnancy: Their characterization and delineation of defects in pregnancies at risk. Prenat Diagn 1991;11:629–635.
  7. Seashore MR, Wappner RS: Genetics in Primary Care and Clinical Medicine. Stamford, Appleton & Lange, 1996.
  8. Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832–1835.
  9. MRC Vitamin Study Research Group: Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991;338:131–137.
  10. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, Willett W: Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of the neural tube defects. JAMA 1989;262:2847–2852.
  11. Mulinare J, Cordero JF, Erickson JD, Berry RJ: Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141–3145.
  12. Werler MM, Shapiro S, Mitchell AA: Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 1993;269:1257–1261.
  13. American College of Obstetricians and Gynecologists: Preconceptional Care. Technical Bulletin No. 205. Washington, American College of Obstetricians and Gynecologist, 1995.
  14. Honebrink A: Folic acid and the prevention of neural tube defects. Am Coll Obstet Gynecol Clin Rev 1999;4:1–16.
  15. Sayers GM, Hughes N, Scallan E, Johnson Z: A survey of knowledge and use of folic acid among women of child-bearing age in Dublin. J Public Health Med 1997;19:328–332.
  16. Bonin MM, Bretzlaff JA, Therrien SA, Rowe BH: Knowledge of periconceptional folic acid for the prevention of neural tube defects. Arch Fam Med 1998;7:438–442.
  17. Bower C, Blum L, O’Daly K, Higgins C, Loutsky F, Kosky C: Promotion of folate for the prevention of neural tube defects: Knowledge and use of periconceptional folic acid supplements in Western Australia, 1992 to 1995. Aust NZ J Public Health 1997;21:716–721.
  18. Centers for Disease Control: Knowledge and use of folic acid by women of childbearing age – United States 1997. JAMA 1997;278:892–893.
  19. Clark NAC, Fisk NM: Minimal compliance with the Department of Health recommendation for routine folate prophylaxis to prevent fetal neural tube defects. Br J Obstet Gynaecol 1994;101:709–710.
  20. Van Allen MI, Kalousek DK, Chernoff GF, Juriloff D, Harris M, McGillivray BC: Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993;47:723–743.
  21. Wald NJ, Hackshaw AK, Stone R, Sourial NA: Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 1996;103:319–324.
  22. Czeizel AE: Nutritonal supplementation and prevention of congenital abnormalities. Curr Opin Obstet Gynecol 1995;7:88–94.

    External Resources

  23. Daly S, Scott JM: The prevention of neural tube defects. Curr Opin Obstet Gynecol 1998;10:85–89.
  24. Canadian Task Force on the Periodic Health Examination: Primary and secondary prevention of neural tube defects. Can Med Assoc J 1994;151:159–167.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50